

HTECH
HIG
H



LIVE
VENDREDI
29 JANVIER
2021

LA FIN DE L'ASPIRINE CHEZ LE CORONARIEN?



Guillaume CAYLA

CHU Nîmes - Département de cardiologie

Groupe de recherche ACTION


Liens d'intérêt

G Cayla has received research grants/consultant fees/lectures fees from Amgen, AstraZeneca, Abbott, Bayer, Biotronik, Bristol-Myers Squibb, Microport, Medtronic, Pfizer, Sanofi-Aventis.

Durée de la DAPT: une (très) longue histoire

BMS

DES



**Prise en compte du
risque hémorragique**

De escalade

De escalation : **intense P2Y₁₂ inhibitor** → **Clopidogrel**

TOPIC, ANTARCTIC, TROPICAL, POPULAR AGE, POPULAR GENETIC

De escalation : retrait aspirine, **P2Y₁₂ monothérapie**

- Clopidogrel après 1 mois (STOP DAPT 2) 3 mois (SMART CHOICE)
- Ticagrelor after 1-3 months (GLOBAL LEADERS/TWILIGHT/ TICO)

Short DAPT duration : retrait P2Y₁₂ inhibitor , **Aspirine seul**
HBR patients (LEADER FREE, ZEUS, ONYX ONE, SENIOR)

Pourquoi garder inhibiteur P2Y12 seul?

Pour




Effet spécifique sur thrombose de stent

Pas d'effet indésirables gastro intestinaux

Pas de résistant biologique avec prasugrel ou ticagrelor

Contre



Resistant biologique au clopidogrel

Les études récentes

STOP DAPT 2

SMART CHOICE

TWILIGHT

TICO

Durée DAPT

1 mois

3 mois

3 mois

3 mois

Après DAPT

Clopi/prasu (1/3)

Clopidogrel/tica (1/5)

100% ticagrelor

100% ticagrelor

%ACS T+


24.5%

25.4%

30.8%


71.1%

Monotherapy @1 month after PCI



Japon N=3009

Primary endpoint:
 CV death/MI/ST/Stroke/TIMI major/minor bleeding:
2.4% vs 3.7% (p sup 0.04)



No excess of ischemic events


Reduction of bleeding events

Monotherapy @3 month after PCI

Study design

SMART-CHOICE

A prospective, multicenter, randomized, open-label, noninferiority trial



- CoCr-EES: cobalt-chromium everolimus eluting stent (Xience series)
- PtCr-EES: platinum-chromium everolimus-eluting stent (Promus series and Synergy)
- BP-SES: bioresorbable polymer: sirolimus-eluting stent (Orsiro)

Primary endpoint: 12-month MACCE


ClinicalTrials.gov NCT02079194

Song YB, ..., Gwon HC, Hahn JY. Am Heart J 2018


ACC LBCT 2019

n=3000, Corée




A Composite events (primary outcome)



A Bleeding (secondary end point)




Monotherapy @3 month after PCI



Monotherapy @3 month after PCI


TIMI major+ MACCE



N=3056, Corée du sud

BK Jim et al JAMA 2020

Monotherapy @3 month after PCI




BK Jim et al JAMA 2020

Meta analyse short DAPT 1-3 mois

Arrêt Aspirine
Arrêt Clopidogrel

GLOBAL LEADERS, SMART CHOICE, STOP DAPT 2, TWILIGHT TICO N=32 145 patients
RESET, OPTIMIZE, REDUCE



Etudes à venir

STOP DAPT 3:


3110 ACS patients, Inhibiteur P2Y12 (prasugrel) **sans aspirine**

TARGET FIRST:

STEMI NSTEMI + MVD avec revascularisation complète :


DAPT 1 mois puis monothérapie P2Y12 (clopi/Tica/Prasu) vs SOC

OAC: Aspirine inutile? NSTE ASC with PCI and OAC



AUGUSTUS PCI

Aspirine réduit numériquement les évènements ischémiques dans le premier mois




Alexander et al Circulation 2020

OAC: Aspirine inutile > 1 an ?



AQUATIC study

AF patients on OAC therapy (+/- SAPT)
History of stent implantation > 12 months
High ischemic risk-Low bleeding risk



Primary ischemic endpoint : CV death, MI, Stroke, any coronary revasc, systemic embolism, ALI
Primary safety endpoint: Major bleeding events (ISTH)

Conclusion

Le risque de thrombose de stent a considérablement diminué

Il est possible de se passer précocement de la bithérapie après DES

Monothérapie après 1 mois: diminution risque hémorragique

Monothérapie immédiate après ATC? STOP DAPT 3

Il persiste des patients à haut risque ischémique et des indications de DAPT au long cours > 12 mois